التفاصيل البيبلوغرافية
| العنوان: |
You have free access to this contentAddition of suberoylanilide hydroxamic acid (Vorinostat) to azacitidine for patients with higher risk myelodysplastic syndromes and azacitidine failure: a phase II add-on study from the Groupe Francophone des Myelodysplasies. |
| المؤلفون: |
Prebet, Thomas, Delaunay, Jacques, Wattel, Eric, Braun, Thorsten, Cony‐Makhoul, Pascale, Dimicoli, Sophie, Wickenhauser, Stephan, Lejeune, Julie, Chevret, Sylvie, Chermat, Fatiha, Fenaux, Pierre, Vey, Norbert |
| المصدر: |
British Journal of Haematology; Mar2018, Vol. 180 Issue 5, p735-737, 3p |
| مصطلحات موضوعية: |
HYDROXAMIC acids, AZACITIDINE, MYELODYSPLASTIC syndromes, DNA methylation, HISTONE deacetylase, GENE silencing, THERAPEUTICS |
| مستخلص: |
The article looks at a study regarding the addition of suberoylanilide hydroxamic acid to azacitidine for patients with higher risk myelodysplastic syndromes and azacitidine failure. It mentions DNA methylation and histone deacetylation (HDAC) are synergistic in terms of gene silencing and the combination of inhibitors. It also mentions toxicity and efficacy of new drugs in combination with hypomethylating agents (HMAs). |
| قاعدة البيانات: |
Complementary Index |
